Cho S, Kim JS, Kang TS, et al. - Researchers utilized data from the multicenter KOMATE and COBIS registries to determine long-term clinical results related to long-term dual antiplatelet therapy (DAPT) following left main coronary artery (LMCA) bifurcation stenting. Overall 1,142 patients treated with a drug-eluting stent for a LMCA bifurcation lesion and had no adverse events for 12 months following the index procedure were examined. They defined two groups of patients: DAPT > 12 months (N = 769) and DAPT ≤ 12 months (N = 373). Major adverse cardiovascular events (MACEs) defined as a composite of cardiac death, myocardial infarction, stroke, and stent thrombosis, observed over a 5-year follow-up, was the primary endpoint. According to the findings, a reduction in MACE rates following LMCA bifurcation stenting was observed in relation to an extended duration of DAPT. The identified significant independent predictors of MACEs included a DAPT score ≥ 2, chronic kidney disease, and age > 75 years.